GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karuna Therapeutics Inc (NAS:KRTX) » Definitions » Total Inventories

Karuna Therapeutics (Karuna Therapeutics) Total Inventories : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Karuna Therapeutics Total Inventories?

Karuna Therapeutics's total inventories for the quarter that ended in Dec. 2023 was $0.00 Mil. Karuna Therapeutics's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Karuna Therapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $31.01.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.


Karuna Therapeutics Total Inventories Historical Data

The historical data trend for Karuna Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karuna Therapeutics Total Inventories Chart

Karuna Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial - - - - -

Karuna Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Karuna Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Karuna Therapeutics  (NAS:KRTX) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Karuna Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

Net-Net Working Capital Per Share (Q: Dec. 2023 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(1262.813+0.75 * 0+0.5 * 0-81.974
-0-0)/38.0775
=31.01

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Karuna Therapeutics's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2023 )/Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=0/0*365 / 4
=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Karuna Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2023 ) / Average Total Inventories (Q: Dec. 2023 )
=0 / 0
=N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Karuna Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Karuna Therapeutics Total Inventories Related Terms

Thank you for viewing the detailed overview of Karuna Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Karuna Therapeutics (Karuna Therapeutics) Business Description

Traded in Other Exchanges
Address
99 High Street, 26th Floor, Boston, MA, USA, 02110
Karuna Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by unmet medical needs. Its product candidate, KarXT is an oral modulator of muscarinic receptors that are located both in the central nervous system, or CNS, and various peripheral tissues.
Executives
Stephen K. Brannan officer: Chief Medical Officer C/O KARUNA THERAPEUTICS, INC., 33 ARCH STREET, SUITE 3110, BOSTON MA 02110
Jason Parker Brown officer: Chief Financial Officer KARUNA THERAPEUTICS, INC., 99 HIGH STREET, 26TH FLOOR, BOSTON MA 02110
Jeffrey M Jonas director ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017
Troy A. Ignelzi officer: Chief Financial Officer C/O ESPERION THERAPEUTICS, INC., 46701 COMMERCE CENTER DRIVE, PLYMOUTH MI 48170
Andrew Craig Miller officer: Chief Operating Officer C/O KARUNA THERAPEUTICS, INC., 33 ARCH STREET, SUITE 3110, BOSTON MA 02110
Laurie J Olson director C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Kane William P Jr officer: Chief Commercial Officer C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
William Meury director, officer: President and CEO C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Atul Pande director C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Charmaine Lykins officer: Chief Commercial Officer C/O KARUNA THERAPEUTICS, INC., 99 HIGH STREET, 26TH FLOOR, BOSTON MA 02110
Steven M Paul director, officer: President & CEO C/O ELI LITTY & CO, LIIY CORPORATE CENTER DC 1093, INDIANAPOLIS IN 46285
Puretech Health Llc 10 percent owner 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Denice Torres director 3 RABBIT RUN DRIVE, NEW HOPE PA 18938
David E. Wheadon director C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045